Neurent Medical, a Galway, Ireland-based company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, closed a $25m Series B financing.
The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV. Fountain Healthcare Partners also participated as a returning investor. As part of this transaction, Drew Burdon of LSP and Gerry Maguire, General Partner, Atlantic Bridge, will join Neurent Medical’s Board of Directors.
The company intends to use the funds to expand its clinical and commercial operations as it prepares for U.S. Food and Drug Administration (FDA) clearance and U.S. commercialization of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™, an innovative in-office treatment for chronic rhinitis.
Led by CEO and Co-Founder Brian Shields, Neurent Medical has developed proprietary Rhinitis Neurolysis Therapy, a treatment option for chronic rhinitis designed to disrupt hyperactive parasympathetic nerves that drive the underlying inflammation. The NEUROMARK™ System’s design, biofeedback monitoring features and advanced algorithmic controls enable the physician to simultaneously treat multiple nerve branches with a high degree of precision, safety and patient comfort.